rs80338701

Variant summary

Our verdict is . The variant received 18 classification points (ACMG Germline Pathogenicity v2019): 18P and 0B. PS1PS3PM1PM2PP3_ModeratePP5_Strong

The NM_000303.3(PMM2):c.357C>A (p.Phe119Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a cumulative frequency of 0.0000352 (AC=55) in the gnomAD database across 1,561,744 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.0000344. In-silico predictor (REVEL) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic/Likely Pathogenic (★★). ClinVar reports functional evidence for this variant: "SCV000399673: In vitro functional studies in E. coli BL21 (DE3) cells demonstrated that the p.Phe119Leu variant results in 25% residual enzyme activity, reduced protein activity and stability, and altered protein quaternary structure as compared to wild type (Kjaergaard et al. 1999" and additional evidence is available in ClinVar. Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.F119= (synonymous): Likely_benign (ClinVar VariationId 1079128, 1 star) This exact variant is curated in the UniProt human variants database as Uncertain Significance.

Frequency

Genomes: 𝑓 0.000039 ( 0 hom., cov: 34)
Exomes 𝑓: 0.000035 ( 0 hom. )

Consequence

PMM2
NM_000303.3 missense

Scores

16
3

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:25O:1

Conservation

PhyloP100: 1.24

Publications

74 publications found
Variant links:
Genes affected
PMM2 (HGNC:9115): (phosphomannomutase 2) The protein encoded by this gene catalyzes the isomerization of mannose 6-phosphate to mannose 1-phosphate, which is a precursor to GDP-mannose necessary for the synthesis of dolichol-P-oligosaccharides. Mutations in this gene have been shown to cause defects in glycoprotein biosynthesis, which manifests as carbohydrate-deficient glycoprotein syndrome type I. [provided by RefSeq, Jul 2008]
PMM2 Gene-Disease associations (from GenCC):
  • congenital disorder of glycosylation type I
    Inheritance: AR Classification: DEFINITIVE Submitted by: Myriad Women's Health
  • PMM2-congenital disorder of glycosylation
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), G2P, ClinGen, PanelApp Australia, Orphanet
  • hyperinsulinemic hypoglycemia with polycystic kidney disease
    Inheritance: AR Classification: STRONG, MODERATE Submitted by: PanelApp Australia, ClinGen

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_000303.3, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACMG Germline Pathogenicity v2019

Classification was made for transcript

Our verdict: Pathogenic. The variant received 18 points.

PS1
Same AA change, 1-star ClinVar pathogenic — strong (PS1); ClinVar contains 1 P/LP entry with the same amino acid change (highest review level: 1 star).
PS3
Well-established functional study supports damaging effect (PS3); SCV000399673: In vitro functional studies in E. coli BL21 (DE3) cells demonstrated that the p.Phe119Leu variant results in 25% residual enzyme activity, reduced protein activity and stability, and altered protein quaternary structure as compared to wild type (Kjaergaard et al. 1999; Andreotti et al. 2013).; SCV000680023: Functional studies show this variant in compound heterozygous state weakens quaternary structure, destabilises the protein and reduces enzyme activity (Andreotti. et al., (2013) and Noelle et al., (2005)).; SCV000833921: Experimental studies have shown that this missense change affects PMM2 function (PMID: 24498599, 26488408, 27053713).; SCV000920013: The most pronounced variant effect results in 10%-<30% of normal activity.; SCV001818601: Functional studies demonstrate a damaging effect with disruption of dimerization and significantly reduced enzyme activity (Andreotti et al., 2013);
PM1
Missense neighbourhood hotspot (≥2 P/LP within ±8 AA, OR ≥ 5 vs. background) — PM1; In-domain: 0 pathogenic, 0 benign rare missense variants.; ±8 AA neighbourhood: 8 pathogenic, 0 benign (OR vs. background: 85.0).
PM2
Very rare in gnomAD for AR/unknown gene (popmax AF < threshold/10) — PM2; GnomAD popmax AF = 0.0000344 — very rare for AR gene (base 0.001, raised to 0.0049 by highest known P/LP ClinVar AF 0.0049) — PM2 moderate.
PP3
Germline meta computational scorer (REVEL/MetaRNN/BayesDel) predicts damaging effect — moderate evidence (PP3); Splicing verdict: not pathogenic.; Germline computational verdict: pathogenic (Moderate).
PP5
ClinVar 2-star pathogenic — strong (PP5); ClinVar submissions overwhelmingly pathogenic (≥10 total, ≥80% P/LP, <10% B/LB) — strong (PP5, count-based); ClinVar germline classification: Pathogenic/Likely Pathogenic, 2 star(s). ClinVar submissions strongly and reliably favor pathogenicity (25/25 total P/LP).

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_000303.3. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
PMM2
NM_000303.3
MANE Select
c.357C>Ap.Phe119Leu
missense
Exon 5 of 8NP_000294.1A0A0S2Z4J6

Ensembl Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
PMM2
ENST00000268261.9
TSL:1 MANE Select
c.357C>Ap.Phe119Leu
missense
Exon 5 of 8ENSP00000268261.4O15305-1
PMM2
ENST00000565221.5
TSL:1
n.188C>A
non_coding_transcript_exon
Exon 3 of 6ENSP00000457932.1H3BV34
PMM2
ENST00000567697.2
TSL:1
n.3525C>A
non_coding_transcript_exon
Exon 1 of 4

Frequencies

GnomAD3 genomes
AF:
0.0000394
AC:
6
AN:
152178
Hom.:
0
Cov.:
34
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000655
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000735
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000436
AC:
8
AN:
183678
AF XY:
0.0000410
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000108
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000348
AC:
49
AN:
1409566
Hom.:
0
Cov.:
30
AF XY:
0.0000330
AC XY:
23
AN XY:
697170
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
32156
American (AMR)
AF:
0.00
AC:
0
AN:
39206
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25442
East Asian (EAS)
AF:
0.00
AC:
0
AN:
37394
South Asian (SAS)
AF:
0.00
AC:
0
AN:
80972
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
50072
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5700
European-Non Finnish (NFE)
AF:
0.0000444
AC:
48
AN:
1080330
Other (OTH)
AF:
0.0000172
AC:
1
AN:
58294
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.454
Heterozygous variant carriers
0
3
6
10
13
16
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000394
AC:
6
AN:
152178
Hom.:
0
Cov.:
34
AF XY:
0.0000538
AC XY:
4
AN XY:
74346
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41430
American (AMR)
AF:
0.0000655
AC:
1
AN:
15278
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5196
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4830
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10614
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000735
AC:
5
AN:
68040
Other (OTH)
AF:
0.00
AC:
0
AN:
2090
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.525
Heterozygous variant carriers
0
1
2
3
4
5
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0000891
Hom.:
0
Bravo
AF:
0.0000189

ClinVar

ClinVar submissions
Significance:Pathogenic
Revision:criteria provided, multiple submitters, no conflicts
View on ClinVar
Pathogenic
VUS
Benign
Condition
15
-
-
PMM2-congenital disorder of glycosylation (16)
8
-
-
not provided (8)
1
-
-
Inborn genetic diseases (1)
1
-
-
PMM2-related disorder (1)

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.99
BayesDel_addAF
Pathogenic
0.53
D
BayesDel_noAF
Pathogenic
0.53
CADD
Pathogenic
28
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.91
D
Eigen
Pathogenic
0.79
Eigen_PC
Pathogenic
0.71
FATHMM_MKL
Uncertain
0.93
D
LIST_S2
Pathogenic
0.98
D
M_CAP
Pathogenic
0.34
D
MetaRNN
Pathogenic
0.99
D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Pathogenic
4.1
H
PhyloP100
1.2
PrimateAI
Pathogenic
0.85
D
PROVEAN
Pathogenic
-5.8
D
REVEL
Pathogenic
0.89
Sift
Uncertain
0.0010
D
Sift4G
Pathogenic
0.0010
D
Varity_R
0.97
gMVP
0.93
Mutation Taster
=4/96
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

Publications

Other links and lift over

For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.